Synlogic, Inc. (SYBX) — SEC Filings
Synlogic, Inc. (SYBX) — 29 SEC filings. Latest: 8-K (Dec 16, 2025). Includes 11 8-K, 5 10-Q, 3 SC 13G/A.
View Synlogic, Inc. on SEC EDGAR
Overview
Synlogic, Inc. (SYBX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 16, 2025: On December 15, 2025, Synlogic, Inc. filed an 8-K report detailing several key events. These include the departure of directors or certain officers, the election of new directors, the appointment of certain officers, and updates to compensatory arrangements for officers. The filing also covers the s
Sentiment Summary
Across 29 filings, the sentiment breakdown is: 4 bearish, 23 neutral, 2 mixed. The dominant filing sentiment for Synlogic, Inc. is neutral.
Filing Type Overview
Synlogic, Inc. (SYBX) has filed 11 8-K, 5 10-Q, 2 DEF 14A, 2 10-K/A, 2 10-K, 3 SC 13G/A, 1 SC 13D/A, 2 SC 13G, 1 SC 13D with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (29)
Risk Profile
Risk Assessment: Of SYBX's 25 recent filings, 4 were flagged as high-risk, 16 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$2.301M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $15.591M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- one
- Mary Beth Dooley
- Dr. Antoine Yver
- Dr. Michael J. Ybarra
- Christopher V. Mirabelli
- Robert J. Mulroy
- Anthony A. Florence, Jr.
- Forest Baskett
- Mohamad H. Makhzoumi
- Patrick J. Kerins
- Scott D. Sandell
- Jacob Ma-Weaver
- Andrew Freedman, Esq.
- Abigail P. Johnson
Industry Context
Synlogic operates in the biotechnology sector, which is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The industry is highly competitive, with many companies vying for funding and market share. Recent trends include a focus on novel therapeutic modalities and personalized medicine, requiring substantial investment and innovation.
Top Tags
corporate-governance (6) · financials (3) · 10-Q (3) · Synlogic (3) · Biotechnology (2) · Net Loss (2) · Cash Burn (2) · SEC Filing (2) · financing (2) · amendment (2)
Executive Compensation
From the most recent DEF 14A filing (Nov 12, 2025):
- Peter Barrett, Ph.D. — Director
- Aoife Brennan, MB, BCh, BAO, MMSc — Director
- Antoine Awad — Director
- Mary Beth Dooley — Director
- Richard P. Shea — Director
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-37566 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 26-1824804 | Company's tax identification number. |
| Net Loss (Q3 2025) | $2.301M | Increased significantly from $0.117M in Q3 2024 |
| Net Loss (9M 2025) | $2.513M | Substantial improvement from $22.645M in 9M 2024 |
| Revenue (Q3 & 9M 2025) | $0 | No revenue generated, down from $8K in 9M 2024 |
| R&D Expenses (9M 2025) | $16K | Drastic reduction from $9.164M in 9M 2024 |
| G&A Expenses (9M 2025) | $2.454M | Decreased from $5.228M in 9M 2024 |
| Cash & Cash Equivalents (Sep 30, 2025) | $15.591M | Sufficient for 12 months of operations at current levels |
| Accumulated Deficit (Sep 30, 2025) | $444.164M | Indicates significant historical losses |
| Full-time Employee | 1 | Remaining after February 2024 corporate restructuring |
| Change in fair value of purchase warrant liability (Q3 2025) | $1.485M | Expense, contrasting with $376K income in Q3 2024 |
| Annual Meeting Date | December 15, 2025 | Date of Synlogic, Inc.'s 2025 Annual Meeting of Stockholders |
| Annual Meeting Time | 9:00 a.m. ET | Start time for the virtual Annual Meeting |
| Record Date | October 24, 2025 | Date for determining stockholders entitled to vote at the Annual Meeting |
| Shares Outstanding | 11,698,919 | Number of common stock shares outstanding and entitled to vote on the Record Date |
Forward-Looking Statements
- {"claim":"SYNLOGIC, INC.'s stock price may experience downward pressure in the short term.","entity":"SYNLOGIC, INC.","targetDate":"3 months","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Synlogic, Inc. (SYBX)?
Synlogic, Inc. has 29 recent SEC filings from Feb 2024 to Dec 2025, including 11 8-K, 5 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SYBX filings?
Across 29 filings, the sentiment breakdown is: 4 bearish, 23 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Synlogic, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Synlogic, Inc. (SYBX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Synlogic, Inc.?
Key financial highlights from Synlogic, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SYBX?
The investment thesis for SYBX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Synlogic, Inc.?
Key executives identified across Synlogic, Inc.'s filings include one, Mary Beth Dooley, Dr. Antoine Yver, Dr. Michael J. Ybarra, Christopher V. Mirabelli and 9 others.
What are the main risk factors for Synlogic, Inc. stock?
Of SYBX's 25 assessed filings, 4 were flagged high-risk, 16 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Synlogic, Inc.?
Recent forward-looking statements from Synlogic, Inc. include guidance on {"claim":"SYNLOGIC, INC.'s stock price may experience downward pressure in the short term.","entity":"SYNLOGIC, INC.","t.